Skip to content

B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Sep 2026 · The Journal of the National Comprehensive Cancer Network · Vol 24 9 · 0 citations · 152 references
Medicine

TL;DR

Pirtobrutinib and CAR T-cell therapy and CAR T-cell therapy have emerged as effective treatment options for refractory or progressive disease after prior treatment with covalent BTK inhibitors.

Abstract

Mantle cell lymphoma (MCL) is a heterogenous subtype of B-cell non-Hodgkin lymphoma (NHL). The treatment landscape of newly diagnosed MCL has evolved in recent years with the incorporation of covalent BTK inhibitors, sensitive assays for the assessment of measurable residual disease (MRD), and predefined maintenance or continuous therapy. Covalent BTK inhibitor-based regimens are also appropriate options for patients with previously untreated classic MCL with TP53 mutations. Pirtobrutinib (a highly selective noncovalent BTK inhibitor) and CAR T-cell therapy (brexucabtagene autoleucel or lisocabtagene maraleucel) have emerged as effective treatment options for refractory or progressive disease after prior treatment with covalent BTK inhibitors. This selection from NCCN Guidelines for B-Cell Lymphomas focuses on the recommendations for the diagnosis and treatment of MCL.

View source

Similar papers

Open access Aug 2026

The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline.

Primary mediastinal B-cell lymphoma (PMBCL) is a distinct clinicopathological entity within the spectrum of aggressive B-cell lymphomas, characterised by unique clinical, immunophenotypic and molecular features. Since publication of the 2019 British Society for Haematology (BSH) Good Practice Paper, there have been imp...

Wendy Osborne, Hannah Bielby, K. Cwynarski et al. · 0 citations
Review Open access Sep 2026

Front-line DLBCL Therapies in Canada in 2026: Biology Matters

Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma responsible for 30–40% of adult non-Hodgkin lymphoma cases. It can develop on its own or from indolent lymphoma.1-2 R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) has been the front-line standard therapy choice since 2002, but a...

Jia Liu, N. Johnson · 0 citations
Review Open access Sep 2026

Front-Line Management of Mantle Cell Lymphoma in Canada: A Practical, Risk-Adapted Approach

Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin lymphoma (NHL) that accounts for approximately 5–7% of all lymphomas.1 Its clinical presentation is heterogeneous, ranging from an indolent leukemic non-nodal subtype that may be managed with observation to highly aggressive disease characterized by TP53 alterat...

J. Desroches, D. Villa · 0 citations
Review Open access Sep 2026

Relapsed Follicular Lymphoma in 2026: Evolving Treatment Strategies in the Canadian Context

Follicular lymphoma (FL) is the most common indolent lymphoma, characterized by a relapsing-remitting course over many years and repeated need for systemic therapy.1 Although outcomes for many patients are excellent, with median overall survival (OS) now exceeding 20 years, a subset of patients experiences early relaps...

M. Keating · 0 citations
Review Oct 2026

Advances in diagnosis and treatment of angioimmunoblastic T-cell lymphoma.

Angioimmunoblastic T-cell lymphoma (AITL) is a peripheral T-cell lymphoma (PTCL) that originates from follicular helper T cells (Tfh) and represents a rare subtype of non-Hodgkin lymphoma (NHL). The disease is characterized by unique morphological, molecular, and clinical features, and exhibits aggressive behavior. Cur...

Qiu-Yan Lin, Lei Fan, Hao-Rui Shen · 0 citations
Review Open access Sep 2026

Sequencing Therapies in Peripheral T-Cell Lymphoma

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of clinically aggressive mature T-cell neoplasms that represent approximately 10% of all non-Hodgkin lymphoma cases.1 According to the most recent World Health Organization (WHO) classification and the International Consensus Classification (ICC),2,3 there a...

D. Ladha, A. Prica · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.